The MINIject device significantly reduced IOP in its first-in-human trial, according to a press release from iSTAR Medical.
The prospective, open, international, multicenter study showed implantation of the MINIject, a microinvasive glaucoma surgery device, in 25 patients with mild to moderate primary open-angle glaucoma resulted in an average 39% IOP reduction to a mean of 14.2 mm Hg at 6 months. Topical medication usage was able to be discontinued in 87.5% of patients, who remained medication-free at 6 months, the release said.
No serious ocular adverse events were recorded. Safety and
Uncategorized